BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Chiron Corporation Ltd. submitted on 1 December 2004 an application for Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
CUBICIN,  through  the  centralised  procedure.  The  eligibility  to  the  centralised  procedure  by  the 
CHMP was agreed upon on 16 September 2004. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
I. Hudson 
Co-Rapporteur:  L. Mathiesen 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
CUBICIN has been given a Marketing Authorisation in the USA on 12 September 2003 and in Israel 
on 13 July 2004. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 1 December 2004.  
The procedure started on 20 December 2004. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 25 February 
2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 1 
March 2005. 
During  the  meeting  on  18  –  21  April  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 April 2005. 
On  26  May  2005,  a  meeting  was  organised  with  the  European  Committee  on  Antimicrobial 
Susceptibility Testing (EUCAST) to discuss the breakpoints. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated List of Questions on 8 July 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 12 August 2005. 
During  the  CHMP  meeting  on  12  –  15  September  2005,  the  CHMP  agreed  on  a  List  of 
Outstanding Issues to be addressed in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding Issues to all CHMP members on 24 October 2005. 
During  the  meeting  on  14  –  17  November  2005,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to CUBICIN on 17 November 2005. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  16 
November 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 19 January 2006. 
1/1 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
